CORRESP Filing
ACTUATE THERAPEUTICS, INC.
Date: Sept. 4, 2025 · CIK: 0001652935 · Accession: 0001683168-25-006692
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-289988
Letter
Actuate Therapeutics, Inc. 1751 River Run, Suite 400
Fort Worth, TX 76107
September 4, 2025
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Chris Edwards
Re: Actuate Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-289988
Ladies and Gentlemen:
Reference is made to our letter, filed as correspondence via EDGAR on September 2, 2025, in which we requested the acceleration of the effective date of the above-referenced registration statement (the " Registration Statement ") for September 4, 2025 at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Baker & Hostetler LLP, requested by telephone that such Registration Statement be declared effective at some other time, in accordance with Rule 461 under the Securities Act of 1933, as amended (the " Act "). We are no longer requesting that such Registration Statement be declared effective at that date and time and we hereby formally withdraw our request for acceleration of the effective date for September 4, 2025 at 4:00 p.m. Eastern Time.
Further, by this letter, pursuant to Rule 461 under the Act, Actuate Therapeutics, Inc. (the " Company ") hereby requests that the effective date of the Registration Statement be accelerated to September 8, 2025, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Baker & Hostetler LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its obligations under the Act.
If you have any questions regarding this request, please contact Janet Spreen of Baker & Hostetler LLP, counsel to the Company, at (216) 861-7564. We also request that we be notified of such effectiveness by a telephone call to Ms. Spreen and that such effectiveness also be confirmed in writing.
Very truly yours,
Actuate Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm Actuate Therapeutics, Inc. 1751 River Run, Suite 400 Fort Worth, TX 76107 September 4, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Chris Edwards Re: Actuate Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-289988 Ladies and Gentlemen: Reference is made to our letter, filed as correspondence via EDGAR on September 2, 2025, in which we requested the acceleration of the effective date of the above-referenced registration statement (the " Registration Statement ") for September 4, 2025 at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Baker & Hostetler LLP, requested by telephone that such Registration Statement be declared effective at some other time, in accordance with Rule 461 under the Securities Act of 1933, as amended (the " Act "). We are no longer requesting that such Registration Statement be declared effective at that date and time and we hereby formally withdraw our request for acceleration of the effective date for September 4, 2025 at 4:00 p.m. Eastern Time. Further, by this letter, pursuant to Rule 461 under the Act, Actuate Therapeutics, Inc. (the " Company ") hereby requests that the effective date of the Registration Statement be accelerated to September 8, 2025, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Baker & Hostetler LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its obligations under the Act. If you have any questions regarding this request, please contact Janet Spreen of Baker & Hostetler LLP, counsel to the Company, at (216) 861-7564. We also request that we be notified of such effectiveness by a telephone call to Ms. Spreen and that such effectiveness also be confirmed in writing. Very truly yours, Actuate Therapeutics, Inc. By: /s/ Daniel M. Schmitt Daniel M. Schmitt President and Chief Executive Officer